Clarivate Analytics, the global leader in providing trusted insights and analytics to accelerate the pace of innovation, revealed that the market value of the most innovative and impactful global life sciences transactions of 2017 increased by 6% totalling US $364 billion, despite a decrease in overall deal volume. The transactions nominated for the annual Clarivate Cortellis Deal of the Year Awards include licensing and mergers and acquisitions. The announcement of the nominees at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco coincided with the Clarivate Deals and Portfolio Annual Review presentation - the foremost independent analysis of the economic trends shaping the life sciences sector in 2017.
Clarivate's Deals and Portfolio Annual Review showcased a deep-dive analysis of 4,234 life sciences transactions. While overall the aggregate dollar value for deals increased from 2016, deal volume dropped by approximately 3% and saw contractions in almost every type of deal structure. This represents a reversal from last year when deal volume was up, but deal dollars were down.
A total of ten 'Deal of the Year' nominees were announced, five each in the categories of M&A and licensing. These include some of the industry's most recognisable names (AstraZeneca, Celgene, and Merck) and life sciences upstarts like Rigontec, CureVac, and IFM Therapeutics. Nominees were recognised for innovations in creative deal structures, the use of novel technology, addressing unmet medical needs and new market penetrations. The analysis was drawn from the Cortellis suite of solutions from Clarivate Analytics. Industry participants may vote for the Deals of the Year at http://info.clarivate.com/DOTY. Winners will be announced in the beginning of February 2018.
This year's Deals and Portfolio Review included a particularly deep investigation into oncology trends, which account for the largest number of M&A transactions by therapeutic area and the largest volume of licensing transactions. All but one of the top 20 dealmakers were active in oncology transactions last year.
Brought to you by Scope e-Knowledge Center, a trusted global partner for digital content transformation solutions - Abstracting & Indexing (A&I), Knowledge Modeling (Taxonomies, Thesauri and Ontologies), and Metadata Enrichment & Entity Extraction.
